Open AccessP031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study
Author(s) -
Sands Bruce,
Marc Pondel,
Marjorie A. Silver,
AnnKatrin Petersen,
Douglas C. Wolf,
Remo Panaccione,
Edward V. Loftus,
Colombel Jf,
Andreas Sturm,
Geert DʼHaens
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000798724.11932.76
Subject(s) - medicine , ulcerative colitis , placebo , cohort , population , vedolizumab , gastroenterology , pathology , disease , environmental health , alternative medicine